Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMA with free AI briefings, catalyst countdowns, and dilution alerts.

IMA · ImageneBio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$126.6M Cash on Hand
40.9mo Cash Runway
Follow IMA by email Get an email when IMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMA, unsubscribe in one click. Privacy

📣 What IMA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

IMA holds $126.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.3M/quarter from operations, an estimated runway of 40.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMA files for a raise →

👥 Who Owns IMA

Insiders 24.3% Other 5%+ holders 14.3% Institutions (39 holders) 54.5% Public and other holders 6.9%
HolderTypeShares% of sharesAs of
Trails Edge Capital Partners, LP Institution (13G, 5%+) 1,176,472 9.44% 2026-04-14
Blue Owl Capital Holdings LP 5%+ holder (13G) 1,135,081 9.11% 2026-09-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 1,128,647 9.06% 2026-06-30
Jonathan Jian Wang
Director · +46,800 options
Insider 1,115,005 8.95% 2025-07-25
Otello Stampacchia
Director · +15,600 options
Insider 936,222 7.52% 2026-04-14
Funicular Funds, LP 5%+ holder (13G) 643,933 5.17% 2025-12-29
Kristin Yarema
Chief Executive Officer, Director · +975,815 options
Insider 493,705 3.96% 2026-08-14
Stephen Hui Wang
Director · +31,200 options
Insider 250,721 2.01% 2025-07-25
Yanina Grant-Huerta
Chief Financial Officer · +56,000 options
Insider 104,000 0.83% 2026-08-14
Robert B Lally
Principal Accounting Officer
Insider 55,582 0.45% 2026-07-16
Erin Butler
Principal Accounting Officer · +26,313 options
Insider 25,551 0.21% 2025-12-30
David P Bonita
Director · +417,809 options
Insider 20,691 0.17% 2026-04-14

Share count 12,456,281 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.